Alterome Therapeutics Raises $132 Million in Series B Financing Led by Goldman Sachs Alternatives

SAN DIEGO–(BUSINESS WIRE)–Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the closing of a $132 million Series B financing. Proceeds from the fundraise will be used to support the advancement of multiple wholly-owned pipeline programs into the clinic, including a highly specific AKT1 E17K inhibitor and a KRAS selective inhibitor. The financing was led by Goldm
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks